Rituximab pharmacokinetics in children and adolescents with de novo intermediate and advanced mature B-cell lymphoma/leukaemia: A Children's Oncology Group report

Matthew J. Barth, Stanton Goldman, Lynette Smith, Sherrie Perkins, Bruce Shiramizu, Thomas G. Gross, Lauren Harrison, Warren Sanger, Mark B. Geyer, Lisa Giulino-Roth, Mitchell S. Cairo

Research output: Contribution to journalArticlepeer-review

21 Scopus citations

Abstract

The ANHL01P1 trial was undertaken to determine pharmacokinetics and safety following the addition of rituximab to French-American-British/Lymphome Malins de Burkitt (FAB/LMB96) chemotherapy in 41 children and adolescents with Stage III/IV mature B-cell lymphoma/leukaemia. Patients received rituximab (375 mg/m2) days -2 and 0 of two induction cycles and day 0 of two consolidation cycles. Highest peak levels were achieved following the second dose of each induction cycle [299 ± 19 and 384 ± 25 μg/ml (Group-B); 245 ± 31 and 321 ± 32 μg/ml (Group-C)] with sustained troughs and t1/2 of 26-29 d. Rituximab can be safely added to FAB chemotherapy with high early rituximab peak/trough levels and a long t1/2.

Original languageEnglish (US)
Pages (from-to)678-683
Number of pages6
JournalBritish Journal of Haematology
Volume162
Issue number5
DOIs
StatePublished - Sep 2013

Keywords

  • CD20
  • Non-Hodgkin lymphoma
  • Pediatric
  • Pharmacokinetics
  • Rituximab

ASJC Scopus subject areas

  • Hematology

Fingerprint

Dive into the research topics of 'Rituximab pharmacokinetics in children and adolescents with de novo intermediate and advanced mature B-cell lymphoma/leukaemia: A Children's Oncology Group report'. Together they form a unique fingerprint.

Cite this